Pharmacological blockage of protein translation sensitizes resistant MM cells to selinexor. (A) U266 cells were treated with selinexor (200 nM, unless otherwise indicated) and/or rocaglamide (50 nM) for 24 hours. The protein expression level of XPO-1, IKZF1, PARP, eIF4E, and Bax were detected via WB, using β-actin as a loading control. The immunoblot is representative of 3 independent experiments. (B) U266 cells were treated with the combination of rocaglamide and selinexor at indicated doses for 4 days. Cell apoptosis was detected using flow cytometry, example dot plots (left) and quantification of replicates (right) for ∗∗P < .01. (C) Cell proliferation was assessed and the combination of rocaglamide and selinexor at indicated doses for 4 days. (D) The CI value was analyzed using CompuSyn software. (E) Dot plot of the combined action of selinexor and rocaglamide. (F) Primary MM cells were cocultured with bone marrow stromal cells and treated with rocaglamide (25 nM) and/or selinexor (50 nM) for 2 days. Cell viability was analyzed using MTS assay. ∗P < .05.